Relacorilant: First Approval

doi:10.1007/s40265-026-02351-9

2026-06-23

PRE

Hannah A. Blair *

DOI：10.1007/s40265-026-02351-9

原文链接

原文求助

摘要

En 中文

Relacorilant（LIFYORLI™）是一种非甾体、选择性糖皮质激素受体II（GR II）拮抗剂，由Corcept Therapeutics公司开发，用于治疗多种实体瘤（包括卵巢癌、输卵管癌、腹膜癌、胰腺癌和前列腺癌）及库欣综合征。Relacorilant于2026年3月25日在美国首次获批，用于与nab-紫杉醇联合治疗既往接受过1～3线系统性治疗（其中至少一线包含贝伐珠单抗）的铂耐药性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者。本文总结了Relacorilant在铂耐药性卵巢癌、输卵管癌或腹膜癌首次获批过程中的关键研发里程碑。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study

Clinical Pharmacology in Drug Development

IF0

2017-10-02

OAAI

Hazel Hunt; Kirsteen Donaldson; Mark Strem; Vanessa Zann; Pui Leung; Suzanne Sweet; Alyson Connor; Dan Combs; Joseph Belanoff

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study Relacorilant联合nab-紫杉醇治疗转移性胰腺导管腺癌：来自开放标签RELIANT研究的结果

The Oncologist

IF0

2024-11-04

PREAI

Borazanci,Erkut H; Bahary,Nathan; Chung,Vincent; Huyck,Timothy K; Kio,Ebenezer A; Chiorean,Elena Gabriela; Skeel,Roland T; Alese,Olatunji B; Cardin,Dana B; Fountzilas,Christos; Hanna,Wahid T; Leal,Alexis D; Lee,Valerie; Noonan,Anne M; Philip,Philip A; Wainberg,Zev A; Pashova,Hristina; Mann,Grace; Oberstein,Paul E

Preclinical efficacy of the selective GR antagonist, CORT125134

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Hunt, Hazel; Belanoff, Joseph; Block, Thad; Shepherd, Stacie P.

Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention 糖皮质激素受体与卵巢癌：从生物学到治疗干预

Biomolecules

IF0

2023-04-05

OAAI

Roberto Buonaiuto; Giuseppe Neola; Sabrina Chiara Cecere; Aldo Caltavituro; Amedeo Cefaliello; Erica Pietroluongo; Pietro De Placido; Mario Giuliano; Grazia Arpino; Carmine De Angelis

Huntsman announces strong third quarter 2017 results

Focus on Surfactants

IF0

2018-01-01

PREAI

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Journal of Clinical Oncology

IF0

2023-10-20

OAAI

Nicoletta Colombo; Toon Van Gorp; Ursula A. Matulonis; Ana Oaknin; Rachel N. Grisham; Gini F. Fleming; Alexander B. Olawaiye; Dorothy D. Nguyen; Andrew E. Greenstein; Joseph M. Custodio; Hristina I. Pashova; Iulia C. Tudor; Domenica Lorusso

A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer 恩扎鲁他胺联合选择性糖皮质激素受体调节剂relacorlant治疗转移性去势抵抗性前列腺癌患者的I期试验

CLINICAL CANCER RESEARCH

IF10.2

2024-03-27

PREAI

Desai, Kunal B.; Serritella, Anthony V.; Stadler, Walter M.; O'Donnell, Peter H.; Sweis, Randy F.; Szmulewitz, Russell Z.

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study relacorilant治疗库欣综合征患者的有效性与安全性（GRACE）：一项多中心、三期、双盲、安慰剂对照、随机撤药研究

The Lancet Diabetes & Endocrinology

IF41.8

2026-02-20

PREAI

Rosario Pivonello; Giorgio Arnaldi; Richard J Auchus; Corin Badiu; Robert S Busch; Salvatore Cannavò; Ulrich Dischinger; Georgiana A Dobri; Diane M Donegan; Atanaska Elenkova; Pouneh K Fazeli; Richard A Feelders; Rogelio Garcia-Centeno; Aleksandra Gilis-Januszewska; Oksana Hamidi; Zeina C Hannoush; Atil Y Kargi; Harold J Miller; Aurelian-Emil Ranetti; Monica Recasens

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

ENDOCRINE PRACTICE

IF4.6

2024-01-01

OAAI

Donegan, Diane M.; Pivonello, Rosario; Stigliano, Antonio; Lardo, Pina; Kearney, Tara; Mezosi, Emese; Ghigo, Ezio; Giordano, Roberta; Mariash, Cary N.; Feelders, Richard A.; Donaldson, Kirsteen; Darpo, Borje; Xue, Hongqi; Custodio, Joseph M.; Hand, Austin L.; Moraitis, Andreas G.

Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)Relacorilant改善了内源性皮质醇增多症（库欣综合征）患者长期研究中的血压，并维持了其他心血管代谢改善

Metabolism

IF0

2025-07-01

PREAI

Auchus,Richard J.; Gilis-Januszewska,Aleksandra; Badiu,Corin; Ranetti,Aurelian-Emil; Kautzky-Willer,Alexandra; Pivonello,Rosario; Dobri,Georgiana; Miller,Harold J.; Niculescu,Dan; Al-Karadsheh,Amer; Aresta,Carmen; Tudor,Iulia Cristina; Pashova,Hristina; Araque,Katherine; Moraitis,Andreas

查看更多内容